Trelegy is NOT Indicated for Interstitial Lung Disease (ILD)
Trelegy (fluticasone furoate/umeclidinium/vilanterol) is FDA-approved exclusively for chronic obstructive pulmonary disease (COPD) and has no indication, evidence base, or guideline support for treating interstitial lung disease. 1
FDA-Approved Indication
- Trelegy is licensed specifically as maintenance treatment for adults with moderate-to-severe COPD who are inadequately controlled on dual therapy (ICS/LABA combination). 1
- The medication combines three components designed for obstructive airway disease: an inhaled corticosteroid (fluticasone furoate), a long-acting beta-2 agonist (vilanterol), and a long-acting muscarinic antagonist (umeclidinium). 1
Why Trelegy Should NOT Be Used in ILD
- ILD represents restrictive lung disease, not obstructive disease—the pathophysiology is fundamentally different from COPD. The bronchodilator components (umeclidinium and vilanterol) target airway smooth muscle and have no therapeutic role in fibrotic or inflammatory interstitial processes.
- Current ILD guidelines make no mention of Trelegy or its components for systemic autoimmune rheumatic disease-associated ILD (SARD-ILD). The 2023 ACR/CHEST guideline for SARD-ILD recommends immunosuppressants (mycophenolate, rituximab, cyclophosphamide, tocilizumab, nintedanib) and explicitly advises against systemic corticosteroids in certain contexts (strong recommendation against glucocorticoids in SSc-ILD due to scleroderma renal crisis risk). 2
- Inhaled corticosteroids lack evidence for ILD treatment. Even in idiopathic pulmonary fibrosis (IPF), inhaled corticosteroids are not recommended for cough management or disease modification. 3
Potential Harms in ILD Patients
- The inhaled corticosteroid component increases pneumonia risk (number needed to harm ~33 per year in COPD populations), which could be particularly dangerous in ILD patients who may already have compromised lung defenses. 4
- Systemic corticosteroid absorption from high-dose inhaled steroids could theoretically worsen certain ILD subtypes (e.g., triggering scleroderma renal crisis in SSc-ILD). 2
Appropriate ILD Management
- For SARD-ILD: Mycophenolate, rituximab, cyclophosphamide, tocilizumab, or nintedanib are guideline-recommended options depending on the specific autoimmune disease and ILD phenotype. 2
- For IPF: Antifibrotic agents (pirfenidone or nintedanib) are the standard disease-modifying therapies. 3
- Short-term, low-dose glucocorticoids may be considered as bridging therapy in select non-SSc SARD-ILD cases, but long-term use should be avoided. 2
Common Pitfall to Avoid
- Do not prescribe COPD medications for ILD based solely on dyspnea or abnormal pulmonary function tests. Always confirm the underlying diagnosis (obstructive vs. restrictive pattern, HRCT findings, clinical context) before selecting therapy. Bronchodilators provide no benefit in pure restrictive disease and delay appropriate immunosuppressive or antifibrotic treatment.